Ceibo Successfully Launches Copper Production at Compañía Minera San Gerónimo (CMSG)
NEW YORK & SANTIAGO, Chile--(BUSINESS WIRE)--Ceibo, a company reinventing copper production and CMSG, a Chilean copper producer, today announced the successful launch of a demo plant using Ceibo's proprietary sulfide leaching technology. Located at CMSG's mine in Northern Chile, the on-site facility has delivered its first copper cathodes, a milestone that signals a new era for scalable, efficient copper recovery.
This achievement marks a major advancement in Ceibo's journey, extracting copper from sulfide ores at a mine using a leaching process compatible with existing infrastructure and significantly faster than conventional methods. Construction of the demo plant began in February 2025 and delivered copper cathodes just three months later. Since going live, the plant has operated continuously, demonstrating both the speed and operational reliability of the solution at scale. This approach unlocks resources once considered uneconomical or too complex to process, offering a cleaner, smarter alternative built for today's resource, climate, and supply chain challenges.
'This isn't just an efficiency gain, it's a blueprint for how the world gets the copper it needs, faster,' said Cristobal Undurraga, CEO, Ceibo. 'Sulfides have historically been out of reach for on-site leaching. Ceibo changes that, delivering a process that integrates with existing operations and accelerates copper recovery at a time when the world urgently needs new supply.'
Across the industry, the shift from oxide to sulfide ores is creating operational challenges, driving demand for new processing approaches. Ceibo's technology increases production without major infrastructure investments, reduces environmental impact and supports the long-term viability of mining projects.
'The first harvest of cathodes using Ceibo's technology is proof that innovation drives everything we do,' said Patricio Rendic, General Manager, CMSG. 'As one of few mining companies producing end-of-chain products, we are redefining mining by diversifying and adding value to our copper. This is the future, where mining and innovation come together to enhance productivity and advance the industry.'
Ceibo's technology combines decades of mining expertise with advanced chemistry, data analytics and AI-driven modeling to optimize performance across ore bodies and site conditions. With global copper demand expected to double by 2035, Ceibo provides tangible proof of a scalable solution that accelerates timelines and reduces risk.
'The future of mining starts with Ceibo,' said Undurraga. 'We are not just imagining a way forward for copper, we are building it.'
About Ceibo:
Ceibo is redefining the future of mining. By combining advanced chemistry, AI-driven modeling and deep operational expertise, Ceibo has engineered a new process to unlock copper from sulfide ores that is faster, smarter, and delivers reduced environmental and infrastructure impact. Founded in 2021, with teams in the US, Canada and Chile, Ceibo brings together metallurgists, chemists, engineers and operators committed to reshaping how critical minerals are produced and pioneering new standards for the future of mining.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Seyltx Announces Positive Non-Human Primate (NHP) and Additional In Vivo Data for its Centrally Acting Inhibitor of GluN2B in Chronic Cough, Paving the Way for Optimized Later-Stage Phase 2 Trials
- Results will be presented at the American Cough Conference on June 7, 2025 - NHP receptor occupancy studies indicate increasing the dose in Phase 2 from 20 mg to 40-80 mg is likely to significantly increase cough suppression before receptor saturation - Oral administration in the Guinea pig model shows cough suppression up to 74% from baseline while staying under the NOAEL - Durability of cough suppression over time promises cough control with TID dose regimen and opens opportunity for once daily reformulation CAMBRIDGE, Mass., June 05, 2025--(BUSINESS WIRE)--Seyltx, Inc. a clinical-stage biotherapeutics company focused on developing innovative therapies to treat chronic cough and other neuronal hypersensitivity indications, today announced promising preclinical results for its lead compound, Ifenprodil. These new findings, to be presented at the American Cough Conference on June 7, 2025, offer critical insights into optimal dosing strategies and therapeutic durability, which will significantly inform the design of upcoming Phase 2 crossover studies planned for 2026. Ifenprodil, a NMDA antagonist with >200x selectivity towards the GluN2B subunit, is being developed to address refractory chronic cough (RCC), a significant unmet medical need, with a follow-on opportunity in chronic cough associated with Idiopathic Pulmonary Fibrosis (IPF-Cough). The company has already completed a Phase 2a trial in IPF-Cough at an exploratory low dose (20 mg TID) which yielded statistically significant reductions in objective cough count of 39% from baseline (at 12 weeks) and statistically significant improvement on multiple patient-reported outcomes. A NHP receptor occupancy (RO) study, conducted in collaboration with Yale University, was performed whereby rhesus monkeys underwent 120-minute PET scans following the intravenous injection of 135 ± 64 MBq (S)-[18F]OF-NB1 (tracer molecule). Ifenprodil was administered via 10-minute intravenous infusion at doses from 0.025 to 1 mg/kg (corresponding to oral human equivalent doses (HED) of 10-400 mg), with PET acquisition commencing 15' post-infusion. Dose-dependent GluN2B receptor occupancy was observed with a calculated EC50 (50% occupancy) of 0.04 mg/kg (HED of ~20 mg) and approximately 80% receptor occupancy predicted at 0.2 mg/kg (HED of ~80 mg). Doses between 40-80 mg TID are therefore expected to achieve 60-80% receptor occupancy, significantly enhancing therapeutic effects compared to the 20 mg TID dose used in the prior Phase 2a trial. In vivo studies conducted in Guinea pigs (GPs; 6-16 animals per group) assessed the antitussive effect of oral doses of Ifenprodil ranging from 1.5 mg/kg to 12 mg/kg (human equivalent doses of 20 to 160 mg). Ifenprodil demonstrated statistically significant (p<0.01) cough count reduction across the dose range of 39-74% following exposure to a tussive agent (1M citric acid). The lowest tested dose of 1.5 mg/kg (HED of 20 mg) resulted in a 39.1% reduction in cough count from baseline, consistent with the 39% reduction seen in the Phase 2a trial. Doubling this dose to an HED of 40 mg TID, which is well-tolerated in humans, improved the cough suppression to 56.0% reduction from baseline. A maximal reduction of 74.4% from baseline was observed at 12 mg/kg (HED 160 mg), a dose under the estimated NOAEL. The therapeutic effect proved durable, lasting up to 8 hours, even as systemic levels of Ifenprodil were cleared. This robust target engagement at the GluN2B subunit supports durable cough control with a TID (three times daily) dose regimen and opens the door for potential once-daily reformulation. These combined preclinical findings suggest an optimal human dose range of 40 to 80 mg for maximal therapeutic benefit, with the 80 mg dose yielding approximately 80% receptor occupancy, safely below levels that have shown adverse events in preclinical models. "These compelling preclinical results represent a significant leap forward in our understanding of Ifenprodil's potential to provide meaningful relief for patients suffering from chronic cough," said Dr. Dietrich Stephan, CEO of Seyltx. "The data not only confirms Ifenprodil's robust antitussive properties but also provides invaluable guidance on optimizing our dosing strategy for future clinical trials. We are excited to integrate these learnings into the design of our upcoming Phase 2 studies, bringing us closer to delivering a truly impactful therapy for this debilitating condition." Dr. Stephan further emphasized, "The promise of addressing GluN2B in the brain is that this target appears to be a central node in the cough reflex, likely providing significant cough control as a monotherapy without addictive potential across the population independent of etiology, if the preclinical data is translatable. The agent also has the potential to be used in combination with future peripherally acting therapies that might be approved." Seyltx plans to incorporate these key learnings into the design of its Phase 2 crossover studies, slated to commence in 2026. About Seyltx: Seyltx ( is a clinical stage biotherapeutics company focused on developing innovative therapies to treat chronic cough and other neuronal hypersensitivity indications. Its lead indication is refractory chronic cough, a significant unmet medical need, with a follow-on opportunity in chronic cough associated with Idiopathic Pulmonary Fibrosis (IPF-Cough). Seyltx's lead compound is Ifenprodil, an NMDA antagonist highly selective towards the GluN2B subunit, has completed a Phase 2a trial in chronic cough associated with IPF. Forward-Looking Statements: Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potential," "possible," "projects," "plans," and similar expressions. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond Seyltx's control. View source version on Contacts Parag ShahChief Operating Officerpshah@ Connectez-vous pour accéder à votre portefeuille
Yahoo
30 minutes ago
- Yahoo
Redfin Reports Some Would-Be Home Sellers Are Stepping Back as Market Tilts Toward Buyers
Many prospective homebuyers are sidelined by near-record costs and economic uncertainty, creating a buyer's market in many parts of the country. That's deterring some would-be sellers. SEATTLE, June 05, 2025--(BUSINESS WIRE)--(NASDAQ: RDFN) — New listings of U.S. homes for sale rose 6.3% year over year during the four weeks ending June 1, one of the smallest increases of the last three months. That's according to a new report from Redfin ( the technology-powered real estate brokerage. New listings declined year over year in 11 of the 50 most populous U.S. metros, with the biggest drops in San Jose, CA and four Florida metros: Orlando, Fort Lauderdale, Tampa and West Palm Beach. Zooming in on recent weeks, new listings fell during the second half of May. While it's typical for listings to decline after peaking in mid-May, this year's drop was the biggest for that time period in a decade. On the buying side, pending home sales declined 0.4% year over year to their lowest May level since 2020, and mortgage-purchase applications fell 3% week over week. Prospective buyers are backing off because housing costs are near record highs, with the median home-sale price up 1.2% year over year and the weekly average mortgage rate approaching 7%, and because the U.S. economy is unpredictable. While there are hundreds of thousands more home sellers than buyers in the market—and new listings are still rising—the recent decline in listings suggests some of this spring's would-be sellers are backing off. The typical home now sells for about 1% less than its asking price, the biggest discount for this time of year since 2020, and just about 28% of homes sell for above their asking price, down from 32% at this time last year. "If a home is in a desirable neighborhood, especially if it's fixed up, it will sell fairly quickly," said Ben Ambroch, a Redfin Premier agent in Milwaukee. "But even that type of home now gets two or three offers, as opposed to the 10 offers it would have gotten a few years ago. Sellers of homes that need work in fringe neighborhoods should be able to find a buyer, but it's important they come to the table with realistic expectations on price and timing, and a willingness to negotiate. Price within a fair range based on the neighborhood, understand that buyers will be inspecting the home, and be prepared to give concessions." For Redfin economists' takes on the housing market, please visit Redfin's "From Our Economists" page. Leading indicators Indicators of homebuying demand and activity Value (if applicable) Recent change Year-over-year change Source Daily average 30-year fixed mortgage rate 6.87% (June 4) Down from 6.97% one week earlier Down from 7.17% Mortgage News Daily Weekly average 30-year fixed mortgage rate 6.89% (week ending May 29) Highest level since Feb. Down from 7.03% Freddie Mac Mortgage-purchase applications (seasonally adjusted) Down 4% from a week earlier (as of week ending May 30) Up 18% Mortgage Bankers Association Redfin Homebuyer Demand Index Down 3% from a month earlier (as of week ending June 1) Up 1% A measure of tours and other homebuying services from Redfin agents Google searches for "home for sale" Up 20% from a month earlier (as of June 1) Up 20% Google Trends ShowingTime stats have been excluded this week to ensure data accuracy. Key housing-market data U.S. highlights: Four weeks ending June 1, 2025 Redfin's national metrics include data from 400+ U.S. metro areas, and are based on homes listed and/or sold during the period. Weekly housing-market data goes back through 2015. Subject to revision. Four weeks ending June 1, 2025 Year-over-year change Notes Median sale price $393,750 1.2% Median asking price $425,975 4.9% Median monthly mortgage payment $2,863 at a 6.89% mortgage rate 4% $20 shy of record high Pending sales 88,141 -0.4% New listings 104,380 6.3% Active listings 1,132,818 14.4% Smallest increase in over a year Months of supply 4 +0.7 pts. 4 to 5 months of supply is considered balanced, with a lower number indicating seller's market conditions Share of homes off market in two weeks 38.7% Down from 42% Median days on market 36 +4 days Share of homes sold above list price 28.4% Down from 32% Average sale-to-list price ratio 99.1% Down from 99.5% Metro-level highlights: Four weeks ending June 1, 2025 Redfin's metro-level data includes the 50 most populous U.S. metros. Select metros may be excluded from time to time to ensure data accuracy. Metros with biggest year-over-year increases Metros with biggest year-over-year decreases Notes Median sale price Philadelphia (11.4%) Detroit (10.6%) Pittsburgh (7.4%) Miami (7.1%) New Brunswick, NJ (6.9%) Oakland, CA (-8.5%) Dallas (-4.5%) Jacksonville, FL (-3.6%) Houston (-2.4%) Austin, TX (-1.6%) Declined in 9 metros Pending sales Cincinnati (10.9%) Chicago (6.5%) Boston (5.7%) Montgomery County, PA (4.7%) Indianapolis (4.2%) Miami (-19.6%) San Jose, CA (-16.2%) Fort Lauderdale, FL (-15.9%) Las Vegas (-15.4%) San Diego (-12.2%) New listings Houston (13.9%) Washington, D.C. (13.5%) Montgomery County, PA (13.2%) Seattle (12%) Cincinnati (11.4%) San Jose, CA (-9%) Orlando, FL (-8.3%) Fort Lauderdale, FL (-6.8%) Tampa, FL (-6.8%) West Palm Beach, FL (-5.5%) Declined in 11 metros To view the full report, including charts, please visit: About Redfin Redfin ( is a technology-powered real estate company. We help people find a place to live with brokerage, rentals, lending, and title insurance services. We run the country's #1 real estate brokerage site. Our customers can save thousands in fees while working with a top agent. Our home-buying customers see homes first with on-demand tours, and our lending and title services help them close quickly. Our rentals business empowers millions nationwide to find apartments and houses for rent. Since launching in 2006, we've saved customers more than $1.8 billion in commissions. We serve approximately 100 markets across the U.S. and Canada and employ over 4,000 people. Redfin's subsidiaries and affiliated brands include: Bay Equity Home Loans®, Rent.™, Apartment Guide®, Title Forward® and WalkScore®. For more information or to contact a local Redfin real estate agent, visit To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin's press release distribution list, email press@ To view Redfin's press center, click here. View source version on Contacts Contact RedfinRedfin Journalist Services:Tana Kelleypress@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
31 minutes ago
- Business Wire
SOLVE Expands AI-Powered Predictive Pricing to Corporate Bonds with Launch of SOLVE Px for the Corporate Bond Market
NEW YORK--(BUSINESS WIRE)--SOLVE, the leading provider of pre-trade data and predictive pricing for fixed income securities markets, today announced the launch of SOLVE Px™ for the Corporate Bond Market, a new AI-driven pricing tool for the high-yield (HY) and investment-grade (IG) corporate bond markets. Covering over 100,000 corporate bonds with industry-leading precision, SOLVE Px provides predictive trade-level pricing that helps traders and portfolio managers act with greater confidence. SOLVE Px is designed to support fixed income professionals who need to make quick, well-informed decisions in often illiquid markets. Built on AI models trained with over 300 feature inputs, including SOLVE's proprietary quote data, the tool delivers pricing that dynamically adjusts to reflect evolving market conditions, enabling buy-side and sell-side users to uncover trade opportunities, manage risk, and refine execution strategies. 'SOLVE Px takes price discovery to another level by providing accurate pricing on securities, regardless of their liquidity,' said Eugene Grinberg, CEO of SOLVE. 'This offering provides real-time insight into the next likely trade level for both investment-grade and high-yield corporate bonds. With predictive pricing, we're helping traders and PMs combine their market judgment with data-driven support to improve outcomes and capture opportunity faster.' SOLVE Px is designed to provide real-time, size-specific pricing data at Bid, Mid, and Offer levels as well as Price, Yield and Spread for each prediction. Delivered via the SOLVE Quotes web application, FTP and FIX feeds, and soon through APIs and Excel add-in, the solution enhances transparency and pricing accuracy by integrating two core components: SOLVE Quotes™ – crowd-sourced bids and offers from market participants, providing rich real-time pricing inputs: Real-time bid, mid, and offer levels delivered across 50,000+ daily securities and 20 million+ daily quotes. AI-Generated Predictive Pricing – a fully machine learning-driven model trained on hundreds of inputs derived from reference data, trade data, and quote data. Together, these components provide a more comprehensive and actionable view of corporate bond pricing. SOLVE Px supports decision-making for traders, portfolio managers, researchers, wealth managers, and investment leaders seeking to boost execution confidence and expand investment visibility. The launch of SOLVE Px for the Corporate Bond Market builds on SOLVE's recent rollout of its Relative Value Analysis tool for municipal bonds, a capability that now also supports corporate bonds. The solution brings powerful visualization capabilities that allow traders and portfolio managers to assess how a bond's value has changed over time, providing clearer context and deeper insight into price behavior in response to market conditions. Grinberg added, 'Combining SOLVE Px with our new Relative Value Analysis tool helps corporate bond traders uncover opportunities in volatile and dynamic markets with unmatched speed and precision. Together, they provide a fuller view of the market, layering real-time predictive pricing with historical context to support smarter trading decisions.' To learn more about SOLVE Px for the Corporate Bond Market, visit SOLVE's website. About SOLVE SOLVE is the leading market data platform provider for fixed-income securities, trusted by sophisticated buy-side and sell-side firms worldwide. Founded in 2011, SOLVE leverages its AI-driven technology and deep industry expertise to offer unparalleled transparency into markets, reduce risk, and save hundreds of hours across front-office workflows. With the largest real-time datasets for Securitized Products, Municipal Bonds, Corporate Bonds, Syndicated Bank Loans, Convertible Bonds, CDS, and Private Credit, SOLVE empowers clients to transform the way they bring new securities to market, trade on secondary markets, and value highly illiquid securities. Headquartered in New York, with offices across the globe, SOLVE is the definitive source for market pricing in Fixed Income markets. For more information, visit *SOLVE Px does not constitute Investment Advice and does not seek to value any security and does not purport to meet the objectives or needs of specific individuals or accounts.
